162 related articles for article (PubMed ID: 1782072)
1. Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
Dodwell DJ; Abbas SK; Morton AR; Howell A
Eur J Cancer; 1991; 27(12):1629-33. PubMed ID: 1782072
[TBL] [Abstract][Full Text] [Related]
2. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
Gurney H; Grill V; Martin TJ
Lancet; 1993 Jun; 341(8861):1611-3. PubMed ID: 8099988
[TBL] [Abstract][Full Text] [Related]
3. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Walls J; Ratcliffe WA; Howell A; Bundred NJ
Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
[TBL] [Abstract][Full Text] [Related]
4. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
5. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
[TBL] [Abstract][Full Text] [Related]
6. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
Nesković-Konstantinović Z; Mitrović L; Petrović J; Stamatović L; Ristović Z
Support Care Cancer; 1995 Nov; 3(6):422-4. PubMed ID: 8564348
[TBL] [Abstract][Full Text] [Related]
7. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
[TBL] [Abstract][Full Text] [Related]
8. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
Body JJ; Louviaux I; Dumon JC
Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
[TBL] [Abstract][Full Text] [Related]
9. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
10. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
11. The use of pamidronate in PTHrP associated hypercalcaemia in infancy.
Buckmaster A; Rodda C; Cowell CT; Ogle G; Dorney S
J Pediatr Endocrinol Metab; 1997; 10(3):301-4. PubMed ID: 9388823
[No Abstract] [Full Text] [Related]
12. Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Hassan BA; Yusoff ZB; Hassali MA; Othman SB; Weiderpass E
Asian Pac J Cancer Prev; 2012; 13(9):4373-8. PubMed ID: 23167346
[TBL] [Abstract][Full Text] [Related]
13. Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate.
Newrick PG; Braatvedt GD; Webb AJ; Sheffield E; Corrall RJ
Postgrad Med J; 1994 Mar; 70(821):231-2. PubMed ID: 8183761
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of midregional parathyroid hormone-related protein in hypercalcaemia of malignancy.
Blind E; Raue F; Götzmann J; Schmidt-Gayk H; Kohl B; Ziegler R
Clin Endocrinol (Oxf); 1992 Sep; 37(3):290-7. PubMed ID: 1424212
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic significance of parathyroid hormone-related protein in tumor patients with hypercalcemia].
Blind E; Raue F; Meinel T; Pecherstorfer M; Räth U; Schmidt-Gayk H; Kohl B; Ziegler R
Dtsch Med Wochenschr; 1993 Mar; 118(10):330-5. PubMed ID: 8453901
[TBL] [Abstract][Full Text] [Related]
17. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
Body JJ; Dumon JC; Thirion M; Cleeren A
J Bone Miner Res; 1993 Jun; 8(6):701-6. PubMed ID: 8328312
[TBL] [Abstract][Full Text] [Related]
18. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).
Ling PJ; A'Hern RP; Hardy JR
Br J Cancer; 1995 Jul; 72(1):206-9. PubMed ID: 7599053
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone related protein and hypercalcaemia in breast cancer.
Bundred NJ; Ratcliffe WA; Walker RA; Coley S; Morrison JM; Ratcliffe JG
BMJ; 1991 Dec; 303(6816):1506-9. PubMed ID: 1782489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
